UK markets closed

Qiagen NV (QIA.DU)

Dusseldorf - Dusseldorf Delayed price. Currency in EUR
Add to watchlist
39.78+0.26 (+0.66%)
As of 07:32PM CEST. Market open.
Full screen
Previous close39.51
Open39.74
Bid39.81 x 0
Ask40.24 x 0
Day's range39.74 - 40.26
52-week range34.05 - 44.48
Volume50
Avg. volume33
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date06 Aug 2024 - 12 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    QIAGEN partners with FBI to develop digital PCR assay for QIAcuity for use in forensics

    Collaboration aims to create novel digital PCR assay to improve successful results in DNA analysis from human samples for use in forensics and human identification // DNA quantification enables law enforcement and forensic researchers to analyze a broader range of evidence more quickly, accurately and reliably // Collaboration strengthens QIAGEN’s leading position in human identification and forensicsVenlo, the Netherlands, and Washington, D.C., May 07, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGE

  • Zacks

    International Markets and Qiagen (QGEN): A Deep Dive for Investors

    Review Qiagen's (QGEN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

  • GlobeNewswire

    QIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inherited disease applications

    QCI Secondary Analysis a cloud-based software directly integrated with QCI Interpret, enabling high-throughput secondary analysis of clinical next-generation sequencing data // New software advances precision medicine by enabling smaller and decentralized labs to adopt NGS testing with efficiency, consistency and confidence // Combination of QCI Secondary Analysis and QCI Interpret provide a secure and compliant environment for trusted and scalable bioinformatics workflows for oncology and inher